Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer

Seasoned healthcare executive and oncologist joins Executive Leadership Team

SECAUCUS, N.J., Dec. 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has been named senior vice president and chief medical officer (CMO), effective immediately.

Dr. Fesko is a seasoned healthcare executive with deep experience in business leadership, clinical practice and academic research. Since joining Quest in 2016, Dr. Fesko has held several roles of increasing responsibility, most recently as vice president of medical affairs and senior medical director for the company's oncology services. As CMO, Dr. Fesko will be responsible for overseeing medical affairs, including clinical development and health plan policy support for new services and care delivery models. He will also lead scientific communications for the company's medical team of approximately 600 MDs and PhDs.

"Strong medical leadership is a critical enabler of our strategy to deliver solutions for the evolving needs of our customers, physicians, health systems and consumers," said Jim Davis, Chairman, CEO and President, Quest Diagnostics. "Yuri is a proven leader who is passionate about improving physician and patient experiences with diagnostic innovations that better care, insights and affordability. Elevating Yuri to CMO ensures his deep medical expertise and caring advocacy for patients and providers infuses the decisions Quest makes at the most strategic levels."

Board certified in oncology, hematology and internal medicine, Dr. Fesko led clinical development of several innovations for Quest, including the company's 500 gene somatic tumor next-generation sequencing panel as well as the company's decentralized clinical trials model. He also pioneered the company's precision pathways model of care, which helps oncologists and pathologists at health systems speed guideline-based biomarker testing for advanced cancers. In addition, he led clinical research on the minimal residual disease (MRD) test technology developed by Haystack Oncology, informing Quest's decision to acquire the company in June 2023 to establish a position in the growing field of cancer recurrence testing. Dr. Fesko speaks on a range of clinical and leadership topics for several preeminent healthcare conferences, such as Clinical Biomarkers & World CDx and the Precision Medicine World Conference.

Prior to joining Quest, Dr. Fesko was medical director of oncology for Duke Cancer Center at Raleigh, N.C., where he focused on genitourinary oncology and multiple myeloma both in clinical practice and for clinical trials, and chief of oncology for Wake County in North Carolina. Dr. Fesko is also a published author of several peer reviewed publications. He sits on the board of directors of a joint venture of Quest Diagnostics and University of Pittsburgh Medical Center.

Dr. Fesko completed his fellowship in hematology and oncology and earned his medical and bachelor's degrees from Case Western Reserve University in Cleveland.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

SOURCE Quest Diagnostics